about
Higher prevalence of antibodies to Borrelia burgdorferi in psychiatric patients than in healthy subjects.Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).Gender differences in the treatment of first-episode schizophrenia: Results from the European First Episode Schizophrenia Trial.Comorbidity of parkinsonism and schizophrenia in a patient treated with clozapine.Visual mismatch negativity among patients with schizophrenia.Attitudes of patients with schizophrenia and depression to psychiatric research: a study in seven European countries.Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST).Glycine serum level in schizophrenia: relation to negative symptoms.Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study.Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study.Visual information processing in recently abstaining methamphetamine-dependent individuals: evoked potentials study.Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.The interrelation of needs and quality of life in first-episode schizophrenia.Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial.Rhythmic finger-tapping task and fast segmentation of neural processing in schizophrenics.Differences in onset of disease and severity of psychopathology between toxoplasmosis-related and toxoplasmosis-unrelated schizophreniaForum – MelancholiaDifferent serine and glycine metabolism in patients with schizophrenia receiving clozapineSubjective well-being with antipsychotic treatmentEffects of haloperidol treatment on prolactin response to D -fenfluramine challenge in acute schizophreniaDoes the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication?Drug induced dementia
P50
Q34112305-82E0B9D0-6A55-45A7-B06E-A80E0815E152Q38486684-69E5FE98-018B-4BF8-880C-5A34CBEC1C94Q38945391-90676F4F-9165-4922-9101-03671A54991BQ39657851-3DFD89B7-ADD7-4235-9CF2-8E2A0D9AFFA5Q39846122-A1AD6A10-E329-4753-87BE-2617C1C56BFEQ39904748-3FEF7B09-ED7F-4928-A6C8-7B6AC6F12DBAQ39963096-8B4CEB54-4FC4-4B69-914C-CF73086F29CCQ43185695-E732B145-0DFA-4845-8C98-3C2036138714Q43264112-CC3DC7A4-9C9A-4B70-A4B7-2926E19BC5E4Q43990949-210C18EC-AD77-4BF3-877A-F35EB270CF0FQ46049842-4BED5D31-94EC-4FD1-9619-89BDA40EF2B4Q46385705-CA3827D4-0B7A-4B5D-A523-3F2E2D0E1818Q46532539-8E90F66F-BC42-46B9-9BA2-A8FAA9BE9259Q46675364-3BF1564D-43C3-490B-A0E9-83C3C1FE553BQ48537147-320EEFB7-A22D-4A43-BDB4-B77C9BB8C59AQ48670296-5CE35895-A8CE-48CD-8DF3-AF6E95BD4DB3Q50536511-47F8C2DE-06F2-4D49-A28E-2C184C6786B5Q52005620-07C12F5E-4566-4DE5-BC18-39F1729ED33BQ56942016-898FD191-4788-423E-B193-1DC745E947D3Q60473543-23BE6B28-82F0-4082-84BC-9448F315AD6AQ60491831-97B02253-7214-45A0-8490-B037830F6123Q60491836-8412B259-256A-48DB-A04F-0BD0330E9AF2Q60491843-AE07CE45-1DFE-4B91-877F-D8344297974AQ60491846-DFD8378C-6C6C-4B4A-BB91-5B4A1E41D8DDQ60491848-4EC116A3-3007-468C-8BFA-EABC9F5CB66A
P50
description
researcher ORCID ID = 0000-0002-6354-8634
@en
name
Jan Libiger
@ast
Jan Libiger
@en
Jan Libiger
@es
Jan Libiger
@nl
type
label
Jan Libiger
@ast
Jan Libiger
@en
Jan Libiger
@es
Jan Libiger
@nl
prefLabel
Jan Libiger
@ast
Jan Libiger
@en
Jan Libiger
@es
Jan Libiger
@nl
P1153
7004110239
P21
P31
P496
0000-0002-6354-8634